Meningitis is relatively rare in the United States and other high-income countries, but it remains a significant global health threat. In the U.S., bacterial meningitis occurs at a rate of roughly 0.3 to 1.5 cases per 100,000 people per year depending on age group, while viral meningitis is considerably more common. Worldwide, bacterial meningitis kills about 1 in 6 people who contract it, and 1 in 5 survivors develops lasting complications.
Viral vs. Bacterial: Which Type Is More Common
Most meningitis cases are caused by viruses, not bacteria. Among meningitis-related hospitalizations in the U.S., about 55% are attributed to viruses, while bacterial meningitis accounts for roughly 22%. Fungal and other causes make up around 7%, and the remaining cases go unspecified. This distinction matters because viral meningitis is generally milder and resolves on its own, while bacterial meningitis is a medical emergency with far higher rates of death and disability.
Viral meningitis often goes unreported or undiagnosed because many people recover without ever being hospitalized. The true number of viral cases is almost certainly higher than hospital records suggest. Enteroviruses are the most common culprit, and infections tend to spike in summer and early fall.
How Rates Differ by Age
Age is the single biggest factor determining your risk. Newborns face the highest rates by a wide margin. Infants under two months old develop bacterial meningitis at a rate of about 46 to 59 cases per 100,000, making it roughly 30 to 40 times more common in this group than in older children or adults. Group B streptococcus is the leading cause of bacterial meningitis in newborns worldwide, affecting an estimated 390,000 infants each year globally.
After infancy, rates drop sharply. Children aged 5 to 17 see bacterial meningitis at a rate of about 0.4 per 100,000. There’s a slight uptick in adolescents and young adults, partly because close-quarters living situations like college dormitories increase transmission of meningococcal bacteria. Adults over 65 face elevated risk again, with recent U.S. data showing about 1.4 cases per 100,000 in that age group.
Recent Trends in the U.S.
Meningococcal disease, one of the most dangerous forms of bacterial meningitis, saw 503 confirmed and probable cases reported in the U.S. in 2024. That was the highest number since 2013, a reminder that cases can fluctuate year to year even in countries with strong vaccination programs. For context, the U.S. population is over 330 million, so this still represents an extremely rare event for any individual.
Bacterial meningitis rates overall declined between 2008 and 2021, with a particularly noticeable dip during 2020 and 2021 when social distancing and masking reduced transmission of many respiratory and close-contact infections. Rates in most age groups have since rebounded partially but remain lower than they were 15 years ago, largely thanks to widespread vaccination.
Where Meningitis Is Most Common
Geography plays a dramatic role. Sub-Saharan Africa’s “meningitis belt,” a band of countries stretching from Senegal to Ethiopia, experiences epidemic-level outbreaks where attack rates can reach up to 1,000 cases per 100,000 people. That’s roughly 700 times the typical rate seen in the U.S. These epidemics tend to occur during the dry season, when dust and low humidity may damage the lining of the nose and throat, making it easier for bacteria to invade.
Outside the meningitis belt, most high-income countries see sporadic cases and occasional localized outbreaks rather than large epidemics. Europe, Australia, and North America all maintain relatively low rates, though clusters can still appear in universities, military barracks, or communities with lower vaccination coverage.
How Vaccines Have Changed the Numbers
Vaccination has been the single most effective tool in reducing meningitis cases over the past two decades. In the Netherlands, introduction of a meningococcal conjugate vaccine led to a 61% overall decline in cases caused by the targeted strains. Among age groups eligible for the vaccine, cases dropped by 82%. Notably, the vaccine also appeared to reduce transmission to unvaccinated age groups, which saw a 57% decline, suggesting meaningful herd protection.
In the U.S., routine childhood vaccines against several of the most common bacterial causes have reshaped the landscape of meningitis. Vaccines targeting pneumococcal bacteria, given to infants starting at two months, have dramatically reduced one of the leading causes of bacterial meningitis in young children. Meningococcal vaccines, typically given at ages 11 to 12 with a booster at 16, protect against four major strains. A separate vaccine targeting a fifth strain (serogroup B) is available for teens and young adults at increased risk.
Severity and Long-Term Impact
Bacterial meningitis remains deadly even with modern treatment. About 1 in 6 people who develop it will die. Among survivors, 1 in 5 experiences lasting complications including hearing loss, seizures, limb weakness, vision problems, and difficulties with memory, speech, or language. Some survivors of meningococcal sepsis, where the bacteria enter the bloodstream, require limb amputations due to tissue damage.
Viral meningitis carries a much better prognosis. Most people recover fully within 7 to 10 days, though fatigue and headaches can linger for weeks. Severe outcomes from viral meningitis are uncommon in people with healthy immune systems, though newborns and immunocompromised individuals face higher risks.
The rarity of meningitis in any individual year can create a false sense of security. Because the disease progresses rapidly, sometimes from first symptoms to life-threatening illness within hours, the low overall numbers don’t diminish the importance of recognizing early warning signs: sudden high fever, severe headache, stiff neck, sensitivity to light, and in infants, a bulging soft spot on the head or unusual irritability.